KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Cost of Revenue: 2010-2025

Historic Cost of Revenue for Pacira BioSciences (PCRX) over the last 16 years, with Sep 2025 value amounting to $34.3 million.

  • Pacira BioSciences' Cost of Revenue fell 11.80% to $34.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.3 million, marking a year-over-year decrease of 16.21%. This contributed to the annual value of $170.4 million for FY2024, which is 7.71% down from last year.
  • Per Pacira BioSciences' latest filing, its Cost of Revenue stood at $34.3 million for Q3 2025, which was down 16.12% from $40.9 million recorded in Q2 2025.
  • Pacira BioSciences' Cost of Revenue's 5-year high stood at $61.9 million during Q4 2022, with a 5-year trough of $31.3 million in Q1 2021.
  • Its 3-year average for Cost of Revenue is $42.2 million, with a median of $40.9 million in 2025.
  • Per our database at Business Quant, Pacira BioSciences' Cost of Revenue soared by 58.73% in 2022 and then fell by 27.65% in 2025.
  • Pacira BioSciences' Cost of Revenue (Quarterly) stood at $39.0 million in 2021, then spiked by 58.73% to $61.9 million in 2022, then declined by 22.97% to $47.7 million in 2023, then declined by 16.37% to $39.9 million in 2024, then declined by 11.80% to $34.3 million in 2025.
  • Its Cost of Revenue stands at $34.3 million for Q3 2025, versus $40.9 million for Q2 2025 and $34.3 million for Q1 2025.